Jefferies Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Jefferies Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-40,000	Closed	-$3.08M	–	1565
2022 Q1	$3.08M	Buy	+40,000	New	+$3.35M	0.02%	538
2021 Q3	–	Sell	-27,600	Closed	-$2.3M	–	1718
2021 Q2	$2.3M	Hold	27,600	–	–	0.01%	707
2021 Q1	$2.08M	Sell	27,600 -17,400	-39%	-$1.42M	0.02%	666
2020 Q4	$3.95M	Buy	45,000 +35,300	+364%	+$2.8M	0.03%	490
2020 Q3	$738K	Sell	9,700 -5,300	-35%	-$536K	0.01%	890
2020 Q2	$1.85K	Hold	15,000	–	–	0.02%	584
2020 Q1	$1.27M	Sell	15,000 -85,500	-85%	-$7.37M	0.01%	908
2019 Q4	$8.5M	Buy	100,500 +31,300	+45%	+$2.36M	0.07%	287
2019 Q3	$4.66M	Buy	+69,200	New	+$5.33M	0.04%	559
2019 Q2	–	Sell	-34,300	Closed	-$3.05M	–	2532
2019 Q1	$3.05M	Sell	34,300 -85,100	-71%	-$7.89M	0.03%	677
2018 Q4	$10.2M	Buy	119,400 +105,400	+753%	+$10M	0.08%	196
2018 Q3	$1.36M	Buy	14,000 +10,200	+268%	+$1.02M	0.01%	1169
2018 Q2	$358K	Buy	3,800 +1,300	+52%	+$114K	﹤0.01%	1769
2018 Q1	$203K	Buy	+2,500	New	+$215K	﹤0.01%	1971
2016 Q4	–	Sell	-26,900	Closed	-$2.49M	–	2215
2016 Q3	$2.49M	Buy	+26,900	New	+$2.53M	0.01%	832
2016 Q1	–	Sell	-27,600	Closed	-$2.89M	–	2213
2015 Q4	$2.89M	Buy	27,600 +22,300	+421%	+$2.33M	0.02%	702
2015 Q3	$558K	Sell	5,300 -37,300	-88%	-$4.98M	﹤0.01%	1460
2015 Q2	$5.83M	Buy	42,600 +40,400	+1,836%	+$5.01M	0.03%	458
2015 Q1	$274K	Sell	2,200 -114,000	-98%	-$12.1M	﹤0.01%	1641
2014 Q4	$10.5M	Buy	+116,200	New	+$9.66M	0.06%	255
2014 Q3	–	Sell	-23,900	Closed	-$1.49M	–	2140
2014 Q2	$1.49M	Buy	+23,900	New	+$1.44M	0.01%	744
2013 Q4	–	Sell	-163,900	Closed	-$11.8M	–	1921
2013 Q3	$11.8M	Buy	+163,900	New	+$10.9M	0.12%	148

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jefferies Group's BMRN Position: Q3 2022 in Review

Jefferies Group increased its BioMarin Pharmaceuticals (BMRN) stake by 795% in Q3 2022, buying an estimated $1.72M and bringing the position to 21,780 shares worth $1.85M. The position accounts for 0.02% of the portfolio, ranked #639.

Jefferies Group first reported a position in BMRN in Q2 2013 and has held it in 37 quarters since. The position peaked at $7.38M in Q3 2018. 551 funds tracked by Wall St. Rank hold BMRN as of Q3 2022.

Jefferies Group held 21,780 shares of BioMarin Pharmaceuticals worth $1.85M as of Q3 2022.
Jefferies Group bought 19,346 BioMarin Pharmaceuticals shares in Q3 2022, an estimated $1.72M.
BioMarin Pharmaceuticals made up 0.02% of Jefferies Group's portfolio in Q3 2022, its #639 holding.
Jefferies Group first reported a position in BioMarin Pharmaceuticals in Q2 2013 and has held it in 37 quarters since.
Jefferies Group's BioMarin Pharmaceuticals position peaked at $7.38M in Q3 2018.
551 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.